B-hINHBE mice|BioMice

Please enter keyword

Gene Editing

By species

By technologies

By strategies

Animal & Cell Models

Humanized animal models

Immune checkpoint humanized mice

Cytokine humanized mice

GPCR humanized mice

Other humanized mice

KO mouse models

Drug target knockout mice

Tool mice

Immunodeficient mice/rats

B-NDG series immunodeficient mice

Other immunodeficient mice/rats

Cell lines

Humanized cell lines

Mouse derived cell lines

Reporter cell lines

Other cell lines

Aged mice

Disease mouse models

Oncology Disease

Autoimmune Disease

Nervous System Disease

Metabolic Disease

Orthopedic Disease

Ophthalmic Disease

Cardiovascular diseases

Urinary System Disease

Surgical disease

Rare Disease

Pharmacology Services

Therapeutic area

Oncology

Metabolic diseases

Autoimmune diseases

Inflammatory diseases

Types of services

In vivo pharmacology

Ex vivo pharmacology

In vitro pharmacology

Pharmacokinetics (PK) assays

Pathological/Toxicological assays

Model/method development

Molecule type

Technology

Resources & Activities

Technical support

News & events

Other Services

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

About Us

Biocytogen animal center

Certifications

Join us

Biocytogen

English|Chinese

English

Chinese

Order

*Country :

China

U.S.A

France

Germany

Netherlands

United Kingdom

Japan

South Korea

Israel

Austria

Hong Kong, China

New Zealand

Russia

Singapore

Taiwan, China

India

Åland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua & Barbuda

Argentina

Armenia

Aruba

Ascension Island

Australia

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bosnia & Herzegovina

Botswana

Brazil

British Indian Ocean Territory

British Virgin Islands

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Canary Islands

Cape Verde

Caribbean Netherlands

Cayman Islands

Central African Republic

Ceuta & Melilla

Chad

Chile

China

Christmas Island

Cocos (Keeling) Islands

Colombia

Comoros

Congo - Brazzaville

Congo - Kinshasa

Cook Islands

Costa Rica

Côte d’Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czechia

Denmark

Diego Garcia

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Honduras

Hungary

Iceland

Indonesia

Iran

Iraq

Ireland

Isle of Man

Italy

Jamaica

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macau, China

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar (Burma)

Namibia

Nauru

Nepal

New Caledonia

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

North Korea

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territories

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn Islands

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Rwanda

Samoa

San Marino

São Tomé & Príncipe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Sint Maarten

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia & South Sandwich Islands

South Sudan

Spain

Sri Lanka

St. Barthélemy

St. Helena

St. Kitts & Nevis

St. Lucia

St. Martin

St. Pierre & Miquelon

St. Vincent & Grenadines

Sudan

Suriname

Svalbard & Jan Mayen

Swaziland

Sweden

Switzerland

Syria

Tajikistan

Zimbabwe

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad & Tobago

Tristan da Cunha

Tunisia

Turkey

Turkmenistan

Turks & Caicos Islands

Tuvalu

U.S. Outlying Islands

U.S. Virgin Islands

Uganda

Ukraine

United Arab Emirates

United Nations

United States

Uruguay

Uzbekistan

Vanuatu

Vatican City

Venezuela

Vietnam

Wallis & Futuna

Western Sahara

Yemen

Zambia

*States :

*City :

*Name :

*Telephone :

*Company :

*Job Title :

*Email :

*Verification Code :

Submit

Home

Animal&Cell Models

Humanized animal models

Humanization of cytokines

Text

B-hINHBE mice

Database

Click order

Strain Name	C57BL/6JNifdc-Inhbe^{tm1(INHBE)Bcgen}/Bcgen	Common Name	B-hINHBE mice
Background	C57BL/6JNifdc	Catalog number	112773
Aliases	Inhbe
NCBI Gene ID	16326

Model validation

mRNA expression analysis

Strain specific analysis of INHBE mRNA expression in wild-type C57BL/6 mice and B-hINHBE mice by RT-PCR. Liver RNA were isolated from wild-type C57BL/6 mice (+/+) and homozygous B-hINHBE mice (H/H), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mouse or human INHBE primers. Mouse Inhbe mRNA was detectable only in wild-type C57BL/6 mice. Human INHBE mRNA was detectable only in homozygous B-hINHBE mice but not in wild-type mice.

Protein expression analysis

Western blot analysis of INHBE protein expression in homozygous B-hINHBE mice. Various tissue lysates were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hINHBE mice (H/H), and then analyzed by western blot with anti-INHBE antibody. 40 μg total proteins were loaded for western blotting analysis. INHBE was detected in liver and kidney of wild-type mice and homozygous B-hINHBE mice, as the antibody cross-recognized both human and mouse INHBE.

mRNA expression analysis

Relative mRNA levels of hINHBE in B-hINHBE mice by qPCR. B-hINHBE mice were randomly divided into two groups (n=3/group, 8 weeks old, male). B-hINHBE mice were fasted or fed 16 hours, and the liver tissue was collected to detect the expression level of human INHBE mRNA by qPCR. The expression level of INHBE in the fasted group of mice was significantly increased. Consistent with the function of INHBE in preventing lipolysis. Values are expressed as mean ± SEM.

The inhibitory efficiency of the nucleic acid drugs against human INHBE

The inhibitory efficiency of the nucleic acid drugs against human INHBE in B-hINHBE mice. B-hINHBE mice were randomly divided into two groups (male, 9-10 weeks old). The human INHBE targeted nucleic acid drugs (provided by a client) and PBS were administered to the mice individually. The nucleic acid drugs was administered in the form of PBS aqueous solution. The mice were sacrificed on day 5, and the liver tissue was collected to detect the expression level of human INHBE mRNA by qPCR. (A) The schematic diagram of experimental processing. (B) The expression of human INHBE mRNA in the liver. The human INHBE in the CPD-1 group was significantly reduced compared to the control group. Values are expressed as mean ± SEM.

The inhibitory efficiency of the nucleic acid drugs against human INHBE

The inhibitory efficiency of the nucleic acid drugs against human INHBE in B-hINHBE mice. B-hINHBE mice were randomly divided into two groups (Female, 10 weeks old). The human INHBE targeted nucleic acid drugs (synthesized according to patents) and PBS were administered to the mice individually. The nucleic acid drug was administered in the form of PBS aqueous solution. The mice were sacrificed on day 14, and the liver tissue was collected to detect the expression level of human INHBE mRNA by qPCR. (Fasting for 16 hours before liver collection.) (A) The schematic diagram of experimental processing. (B) The expression of human INHBE mRNA in the liver. The human INHBE in the siRNA group was significantly reduced compared to the control group. Values are expressed as mean ± SEM. Significance was determined by t-test, **p < 0.01.